Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy

Russell C. Langan, Peter A. Prieto, Richard M. Sherry, Daniel Zlott, John Wunderlich, Gyorgy Csako, Rene Costello, Donald E. White, Steven A. Rosenberg, James C. Yang

Research output: Contribution to journalArticle

Abstract

The aim of the study is to analyze treatment-induced gonadal damage and premature ovarian failure after adoptive cell therapy (ACT) after a cytotoxic lymphodepleting preparative regimen. Records of 66 consecutive females who received ACT at the Surgery Branch, National Cancer Institute, NIH (Bethesda, MD) were reviewed. Patients received a conditioning regimen of high-dose cyclophosphamide (60 mg/kg×2 doses) and fludarabine (25 mg/m 2×5 doses). Some patients also received total body radiation at 200 or 600 cGy. Assessment of ovarian function was determined by analysis of monthly follicle stimulating hormone (FSH) levels, menstrual history, and symptoms. Among patients with serum available and normal pretreatment ovarian function, 21 had a preparative regimen with chemotherapy alone and 5 patients had received chemotherapy with total body radiation. Nine (43%) patients in the chemotherapy cohort and all 5 patients in the chemotherapy plus total body radiation cohort had persistently elevated FSH levels and were given the diagnosis of premature ovarian failure. Twelve (57%) patients had normal FSH levels at 6 months posttreatment. Median age of all patients at treatment was 34 years. Median age of women retaining normal ovarian function was 30 (range, 19-45) vs. 41 years (range, 30-49) for those who did not regain function. The conditioning regimen of 2 doses of cyclophosphamide (60 mg/kg) and 5 doses of fludarabine (25 mg/m2) may induce gonadal damage and premature ovarian failure. Younger age at treatment was associated with a higher frequency of normal ovarian function posttreatment, whereas adding total body radiation was associated with a high risk of ovarian failure.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalJournal of Immunotherapy
Volume34
Issue number4
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Radiation
Drug Therapy
Primary Ovarian Insufficiency
Follicle Stimulating Hormone
Cyclophosphamide
National Cancer Institute (U.S.)
Therapeutics
Serum

Keywords

  • cyclophosphamide
  • follicle stimulating hormone
  • ovarian recovery
  • ovarian toxicity
  • premature ovarian failure

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Langan, R. C., Prieto, P. A., Sherry, R. M., Zlott, D., Wunderlich, J., Csako, G., ... Yang, J. C. (2011). Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. Journal of Immunotherapy, 34(4), 397-402. https://doi.org/10.1097/CJI.0b013e3182187508

Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. / Langan, Russell C.; Prieto, Peter A.; Sherry, Richard M.; Zlott, Daniel; Wunderlich, John; Csako, Gyorgy; Costello, Rene; White, Donald E.; Rosenberg, Steven A.; Yang, James C.

In: Journal of Immunotherapy, Vol. 34, No. 4, 05.2011, p. 397-402.

Research output: Contribution to journalArticle

Langan, RC, Prieto, PA, Sherry, RM, Zlott, D, Wunderlich, J, Csako, G, Costello, R, White, DE, Rosenberg, SA & Yang, JC 2011, 'Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy', Journal of Immunotherapy, vol. 34, no. 4, pp. 397-402. https://doi.org/10.1097/CJI.0b013e3182187508
Langan, Russell C. ; Prieto, Peter A. ; Sherry, Richard M. ; Zlott, Daniel ; Wunderlich, John ; Csako, Gyorgy ; Costello, Rene ; White, Donald E. ; Rosenberg, Steven A. ; Yang, James C. / Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. In: Journal of Immunotherapy. 2011 ; Vol. 34, No. 4. pp. 397-402.
@article{9d14130d6c9349c88183443a38eca6d0,
title = "Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy",
abstract = "The aim of the study is to analyze treatment-induced gonadal damage and premature ovarian failure after adoptive cell therapy (ACT) after a cytotoxic lymphodepleting preparative regimen. Records of 66 consecutive females who received ACT at the Surgery Branch, National Cancer Institute, NIH (Bethesda, MD) were reviewed. Patients received a conditioning regimen of high-dose cyclophosphamide (60 mg/kg×2 doses) and fludarabine (25 mg/m 2×5 doses). Some patients also received total body radiation at 200 or 600 cGy. Assessment of ovarian function was determined by analysis of monthly follicle stimulating hormone (FSH) levels, menstrual history, and symptoms. Among patients with serum available and normal pretreatment ovarian function, 21 had a preparative regimen with chemotherapy alone and 5 patients had received chemotherapy with total body radiation. Nine (43{\%}) patients in the chemotherapy cohort and all 5 patients in the chemotherapy plus total body radiation cohort had persistently elevated FSH levels and were given the diagnosis of premature ovarian failure. Twelve (57{\%}) patients had normal FSH levels at 6 months posttreatment. Median age of all patients at treatment was 34 years. Median age of women retaining normal ovarian function was 30 (range, 19-45) vs. 41 years (range, 30-49) for those who did not regain function. The conditioning regimen of 2 doses of cyclophosphamide (60 mg/kg) and 5 doses of fludarabine (25 mg/m2) may induce gonadal damage and premature ovarian failure. Younger age at treatment was associated with a higher frequency of normal ovarian function posttreatment, whereas adding total body radiation was associated with a high risk of ovarian failure.",
keywords = "cyclophosphamide, follicle stimulating hormone, ovarian recovery, ovarian toxicity, premature ovarian failure",
author = "Langan, {Russell C.} and Prieto, {Peter A.} and Sherry, {Richard M.} and Daniel Zlott and John Wunderlich and Gyorgy Csako and Rene Costello and White, {Donald E.} and Rosenberg, {Steven A.} and Yang, {James C.}",
year = "2011",
month = "5",
doi = "10.1097/CJI.0b013e3182187508",
language = "English (US)",
volume = "34",
pages = "397--402",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy

AU - Langan, Russell C.

AU - Prieto, Peter A.

AU - Sherry, Richard M.

AU - Zlott, Daniel

AU - Wunderlich, John

AU - Csako, Gyorgy

AU - Costello, Rene

AU - White, Donald E.

AU - Rosenberg, Steven A.

AU - Yang, James C.

PY - 2011/5

Y1 - 2011/5

N2 - The aim of the study is to analyze treatment-induced gonadal damage and premature ovarian failure after adoptive cell therapy (ACT) after a cytotoxic lymphodepleting preparative regimen. Records of 66 consecutive females who received ACT at the Surgery Branch, National Cancer Institute, NIH (Bethesda, MD) were reviewed. Patients received a conditioning regimen of high-dose cyclophosphamide (60 mg/kg×2 doses) and fludarabine (25 mg/m 2×5 doses). Some patients also received total body radiation at 200 or 600 cGy. Assessment of ovarian function was determined by analysis of monthly follicle stimulating hormone (FSH) levels, menstrual history, and symptoms. Among patients with serum available and normal pretreatment ovarian function, 21 had a preparative regimen with chemotherapy alone and 5 patients had received chemotherapy with total body radiation. Nine (43%) patients in the chemotherapy cohort and all 5 patients in the chemotherapy plus total body radiation cohort had persistently elevated FSH levels and were given the diagnosis of premature ovarian failure. Twelve (57%) patients had normal FSH levels at 6 months posttreatment. Median age of all patients at treatment was 34 years. Median age of women retaining normal ovarian function was 30 (range, 19-45) vs. 41 years (range, 30-49) for those who did not regain function. The conditioning regimen of 2 doses of cyclophosphamide (60 mg/kg) and 5 doses of fludarabine (25 mg/m2) may induce gonadal damage and premature ovarian failure. Younger age at treatment was associated with a higher frequency of normal ovarian function posttreatment, whereas adding total body radiation was associated with a high risk of ovarian failure.

AB - The aim of the study is to analyze treatment-induced gonadal damage and premature ovarian failure after adoptive cell therapy (ACT) after a cytotoxic lymphodepleting preparative regimen. Records of 66 consecutive females who received ACT at the Surgery Branch, National Cancer Institute, NIH (Bethesda, MD) were reviewed. Patients received a conditioning regimen of high-dose cyclophosphamide (60 mg/kg×2 doses) and fludarabine (25 mg/m 2×5 doses). Some patients also received total body radiation at 200 or 600 cGy. Assessment of ovarian function was determined by analysis of monthly follicle stimulating hormone (FSH) levels, menstrual history, and symptoms. Among patients with serum available and normal pretreatment ovarian function, 21 had a preparative regimen with chemotherapy alone and 5 patients had received chemotherapy with total body radiation. Nine (43%) patients in the chemotherapy cohort and all 5 patients in the chemotherapy plus total body radiation cohort had persistently elevated FSH levels and were given the diagnosis of premature ovarian failure. Twelve (57%) patients had normal FSH levels at 6 months posttreatment. Median age of all patients at treatment was 34 years. Median age of women retaining normal ovarian function was 30 (range, 19-45) vs. 41 years (range, 30-49) for those who did not regain function. The conditioning regimen of 2 doses of cyclophosphamide (60 mg/kg) and 5 doses of fludarabine (25 mg/m2) may induce gonadal damage and premature ovarian failure. Younger age at treatment was associated with a higher frequency of normal ovarian function posttreatment, whereas adding total body radiation was associated with a high risk of ovarian failure.

KW - cyclophosphamide

KW - follicle stimulating hormone

KW - ovarian recovery

KW - ovarian toxicity

KW - premature ovarian failure

UR - http://www.scopus.com/inward/record.url?scp=79955611759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955611759&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3182187508

DO - 10.1097/CJI.0b013e3182187508

M3 - Article

C2 - 21499128

AN - SCOPUS:79955611759

VL - 34

SP - 397

EP - 402

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -